Cambridge Investment Research Advisors
GSK icon

Cambridge Investment Research Advisors’s GSK GSK Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27M Buy
119,567
+5,594
+5% +$296K 0.01% 900
2026
Q1 		$6.29M Sell
113,973
-5,637
-5% -$305K 0.02% 839
2025
Q4 		$5.87M Sell
119,610
-6,776
-5% -$316K 0.02% 837
2025
Q3 		$5.46M Buy
126,386
+13,804
+12% +$539K 0.02% 862
2025
Q2 		$4.32M Sell
112,582
-5,602
-5% -$214K 0.01% 936
2025
Q1 		$4.58M Sell
118,184
-2,713
-2% -$99.3K 0.02% 853
2024
Q4 		$4.09M Sell
120,897
-13,163
-10% -$474K 0.01% 914
2024
Q3 		$5.48M Sell
134,060
-13,028
-9% -$533K 0.02% 751
2024
Q2 		$5.66M Sell
147,088
-2,081
-1% -$87.5K 0.02% 691
2024
Q1 		$6.39M Sell
149,169
-1,245
-0.8% -$51.3K 0.02% 626
2023
Q4 		$5.57M Sell
150,414
-9,745
-6% -$350K 0.02% 648
2023
Q3 		$5.81M Buy
160,159
+8,327
+5% +$296K 0.03% 593
2023
Q2 		$5.41M Buy
151,832
+3,390
+2% +$122K 0.02% 626
2023
Q1 		$5.28M Buy
148,442
+8,039
+6% +$281K 0.03% 603
2022
Q4 		$4.93M Sell
140,403
-31,354
-18% -$1.04M 0.03% 611
2022
Q3 		$5.05M Buy
171,757
+62,175
+57% +$2.36M 0.03% 560
2022
Q2 		$5.96M Buy
109,582
+18,364
+20% +$1.01M 0.03% 507
2022
Q1 		$4.97M Buy
91,218
+352
+0.4% +$19.1K 0.02% 637
2021
Q4 		$5.01M Buy
90,866
+3,028
+3% +$158K 0.02% 645
2021
Q3 		$4.2M Buy
87,838
+1,162
+1% +$58.4K 0.02% 685
2021
Q2 		$4.31M Buy
86,676
+6,538
+8% +$314K 0.02% 697
2021
Q1 		$3.58M Buy
80,138
+818
+1% +$37.1K 0.02% 709
2020
Q4 		$3.65M Sell
79,320
-4,750
-6% -$218K 0.02% 633
2020
Q3 		$3.96M Sell
84,070
-6,116
-7% -$306K 0.03% 538
2020
Q2 		$4.6M Buy
90,186
+11,170
+14% +$573K 0.03% 474
2020
Q1 		$3.74M Sell
79,016
-4,943
-6% -$264K 0.04% 455
2019
Q4 		$4.93M Buy
83,959
+2,697
+3% +$150K 0.04% 471
2019
Q3 		$4.33M Sell
81,262
-2,024
-2% -$104K 0.04% 477
2019
Q2 		$4.17M Sell
83,286
-10,173
-11% -$510K 0.04% 462
2019
Q1 		$4.88M Buy
93,459
+4,370
+5% +$218K 0.05% 377
2018
Q4 		$4.25M Sell
89,089
-1,972
-2% -$97.1K 0.05% 371
2018
Q3 		$4.57M Sell
91,061
-2,478
-3% -$126K 0.04% 396
2018
Q2 		$4.71M Sell
93,539
-1,969
-2% -$99.2K 0.05% 351
2018
Q1 		$4.66M Buy
95,508
+9,210
+11% +$429K 0.05% 341
2017
Q4 		$3.83M Buy
86,298
+4,465
+5% +$206K 0.05% 378
2017
Q3 		$4.15M Sell
81,833
-7,611
-9% -$386K 0.06% 317
2017
Q2 		$4.82M Buy
89,444
+398
+0.4% +$21.2K 0.07% 262
2017
Q1 		$4.69M Buy
89,046
+4,020
+5% +$204K 0.08% 242
2016
Q4 		$4.09M Sell
85,026
-10,857
-11% -$536K 0.08% 243
2016
Q3 		$5.17M Buy
95,883
+9,353
+11% +$513K 0.1% 196
2016
Q2 		$4.69M Buy
86,530
+8,648
+11% +$456K 0.1% 188
2016
Q1 		$3.95M Sell
77,882
-2,447
-3% -$122K 0.09% 210
2015
Q4 		$4.05M Buy
80,329
+10,066
+14% +$513K 0.1% 206
2015
Q3 		$3.38M Sell
70,263
-58
-0.1% -$3.02K 0.1% 204
2015
Q2 		$3.66M Buy
70,321
+6,111
+10% +$344K 0.1% 199
2015
Q1 		$3.7M Buy
64,210
+14,381
+29% +$824K 0.11% 199
2014
Q4 		$2.66M Buy
49,829
+8,243
+20% +$461K 0.08% 233
2014
Q3 		$2.39M Buy
41,586
+6,204
+18% +$380K 0.07% 275
2014
Q2 		$2.37M Buy
35,382
+4,216
+14% +$285K 0.08% 243
2014
Q1 		$2.08M Buy
31,166
+5,520
+22% +$373K 0.08% 246
2013
Q4 		$1.71M Sell
25,646
-3
-0% -$195 0.07% 271
2013
Q3 		$1.61M Buy
25,649
+1,962
+8% +$126K 0.07% 259
2013
Q2 		$1.48M Buy
+23,687
New +$1.5M 0.08% 242

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cambridge Investment Research Advisors's GSK Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its GSK (GSK) stake by 4.9% in Q2 2026, buying an estimated $296K and bringing the position to 119,567 shares worth $6.27M. The position accounts for 0.01% of the portfolio, ranked #900.

Cambridge Investment Research Advisors first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.39M in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Cambridge Investment Research Advisors held 119,567 shares of GSK worth $6.27M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 5,594 GSK shares in Q2 2026, an estimated $296K.
  • GSK made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #900 holding.
  • Cambridge Investment Research Advisors first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • Cambridge Investment Research Advisors's GSK position peaked at $6.39M in Q1 2024.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.